By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Padualaan 8 (postvak 133)

  Utrecht  3584 CH  The Netherlands
Phone: 31-0-30-253-8800 Fax:


Company News
Merus (MRUS) Announces Closing Of Initial Public Offering 5/25/2016 10:15:06 AM
Merus Announces Pricing Of Initial Public Offering 5/19/2016 8:39:56 AM
Merus Announces First Patient Dosed In Phase I/II Trial Evaluating Bispecific Antibody Candidate MCLA-117 In Patients With AML 5/4/2016 7:40:30 AM
Merus To Present Interim Clinical Data From Ongoing Phase I/II Clinical Trial Of Its Lead Bispecific Antibody Candidate, MCLA-128, At The AACR 2016 Annual Meeting 4/18/2016 10:23:49 AM
Merus Announces Issuance Of Three U.S. Patents Strengthening Its Biclonics Technology Platform For The Discovery And Manufacturing Of Human Bispecific Antibodies 3/9/2016 7:59:26 AM
Merus Completes Acquisition Of Surgestone, Provames, Tredemine And Speciafoldine Rights From Sanofi (SNY) 3/7/2016 6:38:05 AM
Merus Buys Four Products from Sanofi (SNY) for €22.5 Million 2/23/2016 6:40:08 AM
Merus Completes Acquisition Of Elantan, Isoket And Deponit Rights From UCB And Announces Date Of Q1 2016 Earnings Release 2/5/2016 6:47:08 AM
Merus Snags Three Cardiovascular Products from UCB Group (UCBJF.PK) in EUR 92 Million Deal 2/2/2016 6:08:49 AM
Merus And Gustave Roussy Form Strategic Collaboration To Develop Innovative Bispecific Antibodies For Therapeutic Immuno-Oncology Applications 1/4/2016 7:10:20 AM